Track Record
Study Register
A complete record of our participation in clinical trials since 2007 – over two decades of research in practice.
Indication / Study
Trial-ID / EudraCT
Phase
Period
PPMS / PriMroSe (Orelabrutinib)
2025-524316-11-00
III
2026 – ongoing
SPMS / Monarch (Orelabrutinib)
2025-524322-18-00
III
2026 – ongoing
Agitation in Alzheimer's / Exciva (SERENADA)
2024-517388-22-00
II/III
2026 – ongoing
Polyneuropathie (ATTR) / AMY DETECT
—
NIS
2026 – ongoing
RRMS / AMGEN 20230309 (ABP 692 vs. Ocrelizumab)
2024-512914-16
III
2024 – 2026
RMS / frexalimab vs teriflunomide
EFC17919B
III
2024 – ongoing
Chronic Neuropathic Pain / LY3848575
J4F-MC-CYAB
II
2024 – ongoing
Migraine prevention / Lu AG09222
2023-508821-28
III
2024 – ongoing
RMS / AIOLOS (Ofatumumab vs. IFN-β/GA & orale DMTs)
COMB157GDE02
NIS
2023 – ongoing
Dementia (Agitation) / AVP-786
2023-504990-19
III
2023 – ongoing
Adults with ADHD / DEXINA
2022-502903-31
III
2023 – ongoing
Elecsys® Amyloid Plasma Panel
RD006263
NIS
2023 – 2025
Major Depressive Disorder / BH-200
2022-002757-26
II
2022 – 2025
RMS / BIIB091 Monotherapy
2022-502552-31
II
2022 – 2026
Psychosis (Alzheimer's) / KarXT
2022-001515-10
III
2022 – 2024
Migraine / Atogepant vs Topiramate
2022-501172-25
III
2022 – 2026
Schizophrenia / BI 425809 (CONNEX-3)
2020-003726-23
III
2021 – 2025
RMS / Fenebrutinib vs teriflunomide
2019-004857-10
III
2021 – ongoing
Chronic non-specific Back Pain / Ver-01
2020-000107-36
III
2021 – 2024
Early Alzheimers Disease / semaglutide
2020-004848-29
III
2021 – 2026
Depressive Episode / Silexan
2020-000688-22
III
2021 – 2023
PPMS / Fenebrutinib vs ocrelizumab
2019-003919-53
III
2021 – ongoing
Alzheimer's / Aducanumab Open-Label
2019-004368-22
IIIb
2020 – 2024
Small-fibre Neuropathie / BIIB074
802NP206
II
2019 – 2021
Mild Alzheimer´s disease / BIIB092
225AD201
II
2018 – 2021
Alzheimers participants at risk
CAPI015A2201J
II/III
2018 – 2019
Mild Alzheimer-Demenz / DAYBREAK
015-005625-39
III
2017 – 2018
Early stage RRMS / Ocrelizumab
2016-002937-31
IIIb
2017 – 2019
Vision GER-BGT 13-10586
—
IV
2016 – 2016
ENGAGE; Aducanumab in Mild AD
2015-000967-15
III
2016 – 2019
RRMS / CASTING; Ocrelizumab
2015-005597-38
III
2016 – ongoing
109MS308 – INSPIRE
—
III
2015 – 2016
101MS408 – REVEAL
—
III
2015 – 2015
Siponimod in SPMS
—
III
2014 – 2023
101MS409 – ESCALATE
—
III
2014 – 2015
CFTY720D2399 – LONGTERMS
—
IV
2014 – 2015
CFTY720DDE02 - NIS PANGAEA
—
IV
2013 – 2021
CFTY720DDE17 – START
—
IV
2013 – 2015
Multiple Regimens Natalizumab (RRMS)
—
II
2011 – 2013
Natalizumab in SPMS
—
III
2011 – 2013
RRMS (Natalizumab to Fingolimod)
—
IIIb
2011 – 2012
Fingolimod & AntiD in RRMS
—
II
2010 – 2012
Siponimod (Optic Neuritis)
—
II
2010 – 2012
Sativex safety registry
—
Obs.
2010 – 2014
Belilumab in Myasthenia Gravis
—
II
2010 – 2015
RRMS / Ono4641
—
II
2010 – 2012
RRMS / Daclizumab
—
II
2010 – 2013
RRMS / FTY (Examining Physician)
—
III
2010 – 2012
RRMS / FTY (Principle Investigator)
—
III
2010 – 2012
RRMS / FTY (Treating Physician)
—
III
2010 – 2012
RRMS / Ocrelizumab
—
II
2008 – 2012
RRMS / FTY (Examining Physician)
—
III
2008 – 2011
Thymectomy in Myasthenia Gravis
—
Eval.
2007 – 2012